Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Child's Nervous System
Erschienen in: Child's Nervous System 11/2010

01.11.2010 | Original Paper

Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells

verfasst von: Kuan-Hsuan Chen, Chuan-Chih Hsu, Wen-Shin Song, Chi-Shuan Huang, Chia-Chen Tsai, Cheng-Deng Kuo, Han-Shui Hsu, Tung-Hu Tsai, Ching-Yao Tsai, Lin-Chung Woung, Shih-Hwa Chiou, Kai-Hsi Lu, Yi-Wei Chen

Erschienen in: Child's Nervous System | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Objects

Cyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to prostaglandins, is overexpressed in a variety of tumors, including medulloblastoma (MB). CD133, a transmembrane glycoprotein, has been suggested as a marker for cancer stem cells in brain tumors. The aim of the present study was to investigate the role of celecoxib, a selective COX-2 inhibitor, in enhancing the effects of ionizing radiotherapy (IR) on medulloblastoma-derived CD133-positive cells (MB-CD133+).

Materials and methods

MB-CD133+ were isolated from two medulloblastoma cell lines (Daoy and UW228). Then, they were treated with celecoxib in different concentrations, and cell viability was assessed. The assays of cell survival, soft agar, radiosensitivity, colony formation, and apoptotic activity in MB-CD133+ treated with celecoxib alone, radiation alone, or celecoxib combined with radiation were further evaluated.

Results

MB-CD133+ showed the self-renew ability to form sphere bodies in vitro and regenerate tumors in vivo. The levels of COX-2 mRNA and protein in MB-CD133+ were significantly higher than those in MB-CD133−. The treatment of 30 μM celecoxib could effectively inhibit the abilities of cell proliferation and colony formation and increase IR-induced apoptosis in treated MB-CD133+. Furthermore, in vivo study demonstrated that celecoxib significantly enhanced radiosensitivity in MB-CD133+-transplanted grafts. Notably, xenotransplantation analysis demonstrated that the treatment of celecoxib could further suppress the expressions of angiogenic and stemnness-related genes in treated MB-CD133+ grafts of SCID mice.

Conclusions

Celecoxib presents the potential of radiosensitizing effect in MB-derived cancer stem cells. Therefore, it should be warranted in future trials to enhance the radiotherapeutic effects in MB patients.
Literatur
1.
Antonarakis E, Heath E, Walczak J, Nelson W, Fedor H, De Marzo A, Zahurak M, Piantadosi S, Dannenberg A, Gurganus R (2009) Phase II, randomized. Placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27:4986CrossRefPubMed
2.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A, Dewhirst M, Bigner D, Rich J (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760CrossRefPubMed
3.
Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist C, Holm S, Gustavsson B, Kagedal B, Kogner P (2008) Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-oncology 10:661CrossRefPubMed
4.
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P, Aigner L, Brawanski A, Bogdahn U, Beier C (2007) CD133+ and CD133-glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010CrossRefPubMed
5.
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82CrossRefPubMed
6.
Cervoni L, Cantore G (1995) Medulloblastoma in pediatric age: a single-institution review of prognostic factors. Childs Nerv Syst 11:80–84, discussion 85CrossRefPubMed
7.
Chen J, Chen Y, SU Y, Tseng S (2007) Celecoxib increased expression of 14-3-3U and induced apoptosis of glioma cells. Anticancer Res 27:2547PubMed
8.
Chen Y, Hsu H, Chen Y, Tsai T, How C, Wang C, Hung S, Chang Y, Tsai M, Lee Y (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3:e2637CrossRefPubMed
9.
Chiou S, Kao C, Lin H, Tseng W, Liu R, Chung C, Ku H, Lin C, Wong T (2006) Monitoring the growth effect of xenotransplanted human medulloblastoma in an immunocompromised mouse model using in vitro and ex vivo green fluorescent protein imaging. Childs Nerv Syst 22:475–480CrossRefPubMed
10.
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165–172CrossRefPubMed
11.
Collins A, Berry P, Hyde C, Stower M, Maitland N (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946CrossRefPubMed
12.
Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544–551CrossRefPubMed
13.
Debucquoy A, Devos E, Vermaelen P, Landuyt W, De Weer S, Van Den Heuvel F, Haustermans K (2009) 18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. Int J Radiat Biol 85:763–771CrossRefPubMed
14.
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2007) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514CrossRefPubMed
15.
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011CrossRefPubMed
16.
Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27:40–48CrossRefPubMed
17.
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386CrossRefPubMed
18.
Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742–2744PubMed
19.
Grosch S, Maier T, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. JNCI J Natl Cancer Inst 98:736CrossRef
20.
Habrand JL, De Crevoisier R (2001) Radiation therapy in the management of childhood brain tumors. Childs Nerv Syst 17:121–133CrossRefPubMed
21.
Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC (2008) PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22:436–448CrossRefPubMed
22.
Hoppe-Hirsch E, Brunet L, Laroussinie F, Cinalli G, Pierre-Kahn A, Renier D, Sainte-Rose C, Hirsch JF (1995) Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst 11:345, discussion 345–346CrossRef
23.
Kang K, Wang T, Woon C, Cheah E, Moore X, Zhu C, Wong M (2007) Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67:888–896PubMed
24.
Kao C, Chiou S, Chen Y, Singh S, Lin H, Liu R, Lo C, Yang C, Chi C, Lee C (2005) Increased expression of osteopontin gene in atypical teratoid/rhabdoid tumor of the central nervous system. Mod Pathol 18:769–778CrossRefPubMed
25.
Kawamori T, Rao C, Seibert K, Reddy B (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409PubMed
26.
Kesari S, Schiff D, Henson J, Muzikansky A, Gigas D, Doherty L, Batchelor T, Longtine J, Ligon K, Weaver S (2008) Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncology 10:300CrossRefPubMed
27.
Kuipers G, Slotman B, Wedekind L, Stoter T, van den Berg J, Sminia P, Lafleur M (2007) Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. Int J Radiat Biol 83:677–685CrossRefPubMed
28.
Liu X, Yao S, Kirschenbaum A, Levine A (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58:4245PubMed
29.
Lu K, Chen Y, Tsai P, Tsai M, Lee Y, Chiang C, Kao C, Chiou S, Ku H, Lin C (2009) Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst 25:543–550CrossRefPubMed
30.
Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso M, Serpe R, Massa E, Astara G, Deiana L (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomark Prev 15:1030CrossRef
31.
Masferrer J, Leahy K, Koki A, Zweifel B, Settle S, Woerner B, Edwards D, Flickinger A, Moore R, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306PubMed
32.
McAdam B, Catella-Lawson F, Mardini I, Kapoor S, Lawson J, FitzGerald G (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272CrossRefPubMed
33.
Milas L (2003) Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am J Clin Oncol 26:S66PubMed
34.
Mutter R, Lu B, Carbone D, Csiki I, Moretti L, Johnson D, Morrow J, Sandler A, Shyr Y, Ye F (2009) A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 15:2158CrossRefPubMed
35.
O’Brien C, Pollett A, Gallinger S, Dick J (2006) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110CrossRefPubMed
36.
Pakos E, Ioannidis J (2004) Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 60:888–895PubMed
37.
Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang D (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65:6207CrossRefPubMed
38.
Pawlik T, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59:928–942CrossRefPubMed
39.
Pawlik T, Keyomarsi K (2004) Colon carcinoma radiosensitivity and cell cycle arrest is dependent on both p53/p21 status and radiation dose. Proc Am Assoc Cancer Res 2004:310
40.
Prince M, Sivanandan R, Kaczorowski A, Wolf G, Kaplan M, Dalerba P, Weissman I, Clarke M, Ailles L (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci 104:973CrossRefPubMed
41.
Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J, Dirks P (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821PubMed
42.
Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T, Henkelman R, Cusimano M, Dirks P (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMed
43.
Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S, Santuccione A, Bernays R, Heppner FL, Schuller U, Grotzer M, Moch H, Schraml P, Marino S (2010) Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29:1845–1856CrossRefPubMed
44.
45.
Whelan HT, Krouwer HG, Schmidt MH, Reichert KW, Kovnar EH (1998) Current therapy and new perspectives in the treatment of medulloblastoma. Pediatr Neurol 18:103–115CrossRefPubMed
Metadaten
Titel
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells
verfasst von
Kuan-Hsuan Chen
Chuan-Chih Hsu
Wen-Shin Song
Chi-Shuan Huang
Chia-Chen Tsai
Cheng-Deng Kuo
Han-Shui Hsu
Tung-Hu Tsai
Ching-Yao Tsai
Lin-Chung Woung
Shih-Hwa Chiou
Kai-Hsi Lu
Yi-Wei Chen
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Child's Nervous System / Ausgabe 11/2010
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-010-1190-2

Weitere Artikel der Ausgabe 11/2010

Child's Nervous System 11/2010 Zur Ausgabe

Original Paper

Ventriculosubgaleal shunt procedure and its long-term outcomes in premature infants with post-hemorrhagic hydrocephalus

Letter to the Editor

Reply to Dr H Gardner

Original Paper

Study of brain growth in children—a new approach to volume measurements using MRI-reconstructed 3D neuroimaging

Letter to the Editor

Posterior fossa tumors in children with neurofibromatosis type 1 (NF1)

Letter to the Editor

Syringomyelia secondary to shunt malfunction

Case Report

Castleman’s disease associated with a cerebellar chordoid meningioma and intestinal lymphangiectasia

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.